glp-1 for sleep apnea fda approved Huge news: has Zepbound (tirzepatide- GLP-1/GIP receptor agonist) the treatment of moderate to severe obstructive in adults with obesity. As a cardiologist, this is a huge deal Good news on the GLP-1

mean age, 16 years) who initiated therapy with GLP1-RA from January 1, 2018, to May 20, 2023

Servings Per Container: 60

The answer, drawn from interviews with 30 adults across the United States, is far more complex than any before-and-after photo

Realistically, many users experience: 510 pounds lost in the first month, primarily due to reduced appetite and calorie intake 1020% total body weight loss over 612 months (depending on the drug) Slower, steady progress as the body adjusts to the medication Sustained weight loss is often achievable with continued use of the medication after reaching your goal weight To shed light on whats truly typical, we asked a provider with firsthand experience

We did not pool mortality data in a meta-analysis because most deaths occurred in a single trial which recruited exclusively patients at increased cardiovascular risk (25 deaths with tirzepatide and 35 deaths with insulin glargine) [21]

Two GLP-1s (Saxenda and Wegovy) are currently approved for use in adolescents ages 12 and up